| 生物活性 |
Methyl rosmarinate is an orally active hydroxycinnamic acid that exhibits an IC50 of 24.70 μM and a Ki of 15.29 μM against PTP1B, an IC50 of 41.46 μg/mL against BChE, a Ki of 0.61 mM against mushroom tyrosinase, and an IC50 of 2.50 μM against SARS-CoV-2 3CLpro; it downregulates the phosphorylation levels of ERK, JNK, p38, Smad2, and Smad3, activates erythrocyte BPGM to promote 2,3-BPG production, induces apoptosis in fibroblasts, prolongs the survival time of hypoxic mice, improves insulin sensitivity, binds to SARS-CoV-2 3CLpro to inhibit viral replication, induces glioblastoma cell death, activates the TGR5/AMPK axis to reduce ROS and MDA levels, exhibits inhibitory activity against MMP-1, and can be used in research related to pulmonary fibrosis, hypoxia-induced injury, type 2 diabetes, Alzheimer's disease, hyperpigmentation disorders, coronavirus disease 2019, glioblastoma, and myocardial ischemia-reperfusion injury. |
| IC50 & Target |
Tyrosinase:0.28 mM |
体外研究 (In Vitro) |
Methyl rosmarinate (10-160 μM; 48 h) 对 L929 细胞表现出细胞毒性,IC50 为 76.27 μM。 Methyl rosmarinate (10-40 μM; 48 h) 降低经 TGF-β1 刺激的 L929 细胞中的细胞外基质蛋白积累。 Methyl rosmarinate (20-40 μM; 12-72 h) 抑制 TGF-β1 刺激的小鼠成纤维细胞 L929 的增殖和迁移,提高细胞的凋亡率。 Methyl rosmarinate (20-40 μM; 48 h) 在经 TGF-β1 刺激的小鼠成纤维细胞 L929 中升高促凋亡蛋白 Bax, cleaved caspase 3, and cleaved caspase 9 的表达水平,降低抗凋亡蛋白 Bcl-2 的表达水平,抑制 TGF-β1/Smad 和 MAPK 信号通路的磷酸化,减轻细胞的纤维化反应。 Methyl rosmarinate 可竞争性、可逆性地抑制重组人 PTP1B 酶的活性,其 IC50 为 24.7 μM,Ki 为 15.29 μM。 Methyl rosmarinate (6.25-25 μM; 24 h) 可作为胰岛素增敏剂,增强完全分化的 C2C12 肌管中胰岛素刺激的葡萄糖摄取,增强完全分化的 C2C12 肌管中胰岛素刺激的糖原合成,胰岛素信号通路,提升胰岛素刺激的 IRS-1 和 Akt 磷酸化水平,且不改变 PTP1B 蛋白表达量。 Methyl rosmarinate 可抑制丁酰胆碱酯酶 (BChE),IC50 为 41.46 µg/mL,但对乙酰胆碱酯酶 (AChE) 无显著抑制作用。 Methyl rosmarinate (0.01-0.4 mM; 2 min preincubation, 5 min reaction) 可抑制蘑菇酪氨酸酶的二酚酶活性,Ki 为 0.61 mM,抑制酵母 α-葡萄糖苷酶活性。 Methyl rosmarinate 可作为纯化 SARS-CoV-2 3CLpro 的变构抑制剂,其 IC50 为 2.5 μM,Ki 为 1.27 μM,Kd 为 5.93 μM。 Methyl rosmarinate (1-200 μM; 52 h total) 可抑制 Huh7 细胞中 SARS-CoV-2 复制子的复制,其 EC50 为 18.91 μM,且在 200 μM 浓度下仅表现出中度细胞毒性。 Methyl rosmarinate (5-60 μM; 72 h) 可呈剂量依赖性降低人胶质母细胞瘤 U87 (IC50 = 9.8 μM) 和 T98 (IC50 = 13 μM) 细胞系的活力。 Methyl rosmarinate (9.8-19.6 μM (U87 cells); 13-26 μM (T98 cells); 72 h) 可诱导 U87 细胞发生 subG0 期和 S 期阻滞,诱导 T98 细胞发生 subG0 期和 G2/M 期阻滞。 Methyl rosmarinate (9.8-19.6 μM (U87 cells); 13-26 μM (T98 cells); 48 h) 可剂量依赖性地抑制 U87 和 T98 细胞系的迁移。 Methyl rosmarinate 抑制纯化的人 MMP-1,其 IC50 为 14.7 μM。
Cell Cytotoxicity Assay
| Cell Line: |
mouse fibroblast L929 cells |
| Concentration: |
0, 10, 20, 40, 80, and 160 μM |
| Incubation Time: |
48 h |
| Result: |
Exhibited cytotoxicity toward L929 cells, with an IC50 value of 76.27 μM. Reduced cell viability to 92.53% of the control at 80 μM. Reduced cell viability to 48.82% of the control at 160 μM. |
Western Blot Analysis
| Cell Line: |
TGF-β1-stimulated mouse fibroblast L929 cells |
| Concentration: |
10, 20, 40 μM |
| Incubation Time: |
48 h (following 72 h of TGF-β1 stimulation) |
| Result: |
Dose-dependently reduced the elevated expression of collagen-I, collagen-III, vimentin, α-SMA, and snail proteins induced by TGF-β1 stimulation. Caused significant, concentration-dependent decreases in the expression of all these fibrosis-associated proteins relative to TGF-β1-only treated cells. |
Cell Proliferation Assay
| Cell Line: |
TGF-β1-stimulated mouse fibroblast L929 cells |
| Concentration: |
20, 40 μM |
| Incubation Time: |
12, 24, 48, 72 h (co-treated with TGF-β1) |
| Result: |
Significantly inhibited the increased proliferation of L929 cells induced by TGF-β1 at all measured time points. Showed statistically significant inhibitory effects at both 20 μM and 40 μM concentrations relative to TGF-β1-only treated cells. |
Cell Migration Assay
| Cell Line: |
TGF-β1-stimulated mouse fibroblast L929 cells |
| Concentration: |
20, 40 μM |
| Incubation Time: |
24, 48 h (following TGF-β1 induction) |
| Result: |
Significantly reduced the migration rate of TGF-β1-stimulated L929 cells at both 24 and 48 h. Showed a stronger inhibitory effect at 40 μM concentration relative to the 20 μM concentration. |
Apoptosis Analysis
| Cell Line: |
TGF-β1-stimulated mouse fibroblast L929 cells |
| Concentration: |
20, 40 μM |
| Incubation Time: |
48 h (following TGF-β1 induction) |
| Result: |
Significantly increased the apoptosis rate of TGF-β1-stimulated L929 cells. Increased apoptosis rate to 5.49% at 20 μM relative to 3.53% in TGF-β1-only treated cells. Increased apoptosis rate to 10.32% at 40 μM relative to 3.53% in TGF-β1-only treated cells. |
Western Blot Analysis
| Cell Line: |
TGF-β1-stimulated mouse fibroblast L929 cells |
| Concentration: |
20, 40 μM |
| Incubation Time: |
48 h (following TGF-β1 induction) |
| Result: |
Increased expression of pro-apoptotic proteins Bax, cleaved caspase 3, and cleaved caspase 9 in a dose-dependent manner relative to TGF-β1-only treated cells. Decreased expression of anti-apoptotic protein Bcl-2 in a dose-dependent manner relative to TGF-β1-only treated cells.\nDose-dependently reduced the phosphorylation ratios of p-Smad2/Smad2, p-Smad3/Smad3, p-ERK/ERK, p-JNK/JNK, and p-p38/p38 in TGF-β1-stimulated L929 cells. Caused statistically significant decreases in phosphorylation ratios at both 20 and 40 μM relative to TGF-β1-only treated cells. |
Western Blot Analysis
| Cell Line: |
fully differentiated C2C12 myotubes |
| Concentration: |
6.25, 12.5 and 25 μM |
| Incubation Time: |
24 h |
| Result: |
Did not alter PTP1B protein expression. Dose-dependently enhanced insulin-stimulated phosphorylation of IRS-1 and Akt, with significant increases observed at 12.5 and 25 μM relative to the insulin-only group. |
Cell Viability Assay
| Cell Line: |
human glioblastoma U87, T98 cell lines |
| Concentration: |
5, 15, 30, 45, 60 μM |
| Incubation Time: |
72 h |
| Result: |
Reduced cell viability in a dose-dependent manner in both cell lines. Reached a half maximal inhibitory concentration (IC50) of 9.8 μM in U87 cells and 13 μM in T98 cells. Induced morphological changes including shrinking and death at higher concentrations. |
Cell Cycle Analysis
| Cell Line: |
human glioblastoma U87, T98 cell lines |
| Concentration: |
9.8, 19.6 μM (U87 cells); 13, 26 μM (T98 cells) |
| Incubation Time: |
72 h |
| Result: |
Increased subG0/G1 phase from 1.9945% to 16.331% and S phase from 7.318% to 15.249% in U87 cells. Increased subG0/G1 phase from 0.835% to 5.179% and G2/M phase from 4.502 to 16.551 in T98 cells. Caused statistically significant changes in both cell lines. |
|
体内研究 (In Vivo) |
Methyl rosmarinate (20 mg/kg;口服;每日;第 3 天至第 28 天) 可显著减轻 Bleomycin (MS-R86735) 诱导的 C57BL/6 雄性小鼠肺纤维化。 Methyl rosmarinate (25-75 mg/kg,腹腔注射;每日 1 次;连续 3 天,) 可延长常压密闭缺氧小鼠的存活时间,通过降低炎症因子、改善组织氧化应激、缓解组织病理损伤及减轻组织缺氧,保护小鼠免受高海拔野外缺氧的损伤,增强暴露于高海拔野外缺氧环境的小家鼠 (Mus musculus) 红细胞糖酵解通路活性,激活 BPGM,并提升 2,3-BPG 水平,进而改善红细胞的氧释放能力。 Methyl rosmarinate (6.25-25 mg/kg;灌胃;每日;7 周) 可改善高脂饮食/ Streptozotocin (MS-Q80520) 诱导的 2 型糖尿病小鼠的胰岛素敏感性,恢复糖脂稳态,保护骨骼肌与器官功能,并增强 β 细胞功能。 Methyl rosmarinate (50-200 mg/kg;腹腔注射;结扎前 3 小时单次给药) 可通过激活 TGR5/AMPK 信号轴,呈剂量依赖性地改善心肌缺血再灌注损伤模型 Mus musculus (小鼠) 的心功能,减轻其心肌损伤、氧化应激及线粒体损伤。
| Animal Model: |
C57BL/6 (male, bleomycin-induced pulmonary fibrosis model) |
| Dosage: |
20 mg/kg |
| Administration: |
p.o.; daily; day 3 to day 28 |
| Result: |
Significantly improved mouse body weight and reduced lung fibrosis as visualized by small animal MicroCT. Improved lung structure, reduced inflammatory cell infiltration, and decreased collagen deposition compared to the bleomycin-only group. Reduced Ashcroft fibrosis score from ~5.2 in the bleomycin-only group to ~1.8. Reduced collagen deposition area from ~50% in the bleomycin-only group to ~45%. Significantly reduced lung tissue levels of fibrosis-associated proteins collagen-I and collagen-III compared to the bleomycin-only group.
|
| Animal Model: |
BALB/c (male and female, 18-22 g) |
| Dosage: |
25 mg/kg; 50 mg/kg; 75 mg/kg |
| Administration: |
i.p.; daily; 3 days |
| Result: |
Prolonged survival time by 20.15% (31.89 minutes) at 25 mg/kg vs. blank control. Prolonged survival time by 24.35% (33.00 minutes) at 50 mg/kg vs. blank control. Prolonged survival time by 24.19% (32.96 minutes) at 75 mg/kg vs. blank control. Showed statistically significant survival time increases across all dose groups vs. blank control. |
| Animal Model: |
C57BL/6 J (male, 6 weeks old, high-fat diet + streptozotocin-induced type 2 diabetes) |
| Dosage: |
6.25 mg/kg; 25 mg/kg |
| Administration: |
i.g.; daily; 7 weeks |
| Result: |
Reversed decreased body weight and elevated fasting blood glucose levels, with effects comparable to metformin. Reduced weekly food intake and decreased glycosylated serum protein (GSP) levels in a dose-dependent manner. Improved glucose clearance during GTT and insulin sensitivity during ITT, as evidenced by reduced area under the curve (AUC) values compared to vehicle-treated T2D mice. Increased fasting serum insulin (FINS) levels; the 25 mg/kg dose significantly reduced the homeostasis model assessment of insulin resistance (HOMA-IR) index and improved the homeostasis model assessment of β-cell function (HOMA-β) index. Improved lipid profiles by reducing total cholesterol (T-CHO), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while increasing high-density lipoprotein cholesterol (HDL-C) levels. Reversed T2D-induced loss of skeletal muscle mass (improved indexes of extensor digitorum longus, tibialis anterior, soleus, gastrocnemius, and quadriceps muscles) and protected against skeletal muscle fiber atrophy. Elevated glycogen synthesis in skeletal muscle, restored insulin-stimulated phosphorylation of IRS-1 and Akt in skeletal muscle, and downregulated PTP1B protein expression in skeletal muscle (the 25 mg/kg dose returned PTP1B expression to normal levels). The 25 mg/kg dose reduced liver and kidney indexes, attenuated liver steatosis and renal tubule vacuolation, and decreased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, with no observed toxicity in normal mice. |
| Animal Model: |
C57BL/6 J (male, 6-8 weeks old, 20-22 g, myocardial ischemia-reperfusion injury model via left anterior descending coronary artery ligation for 30 minutes followed by reperfusion; some groups received tail vein injection of AV-TGR5, AV-sh-TGR5, or negative control AAV9 3 weeks prior to injury) |
| Dosage: |
50 mg/kg; 100 mg/kg; 200 mg/kg |
| Administration: |
i.p.; single dose 3 h pre-ligation |
| Result: |
Increased LVDP, +dp/dtmax, and −dp/dtmax, and decreased LVEDP dose-dependently compared to MIRI controls. Reduced serum CK-MB and LDH levels, and reduced myocardial infarct size dose-dependently compared to MIRI controls. Preserved myocardial fiber structure, reduced inflammatory cell infiltration, hemorrhage, edema, and necrosis; reduced myocardial fibrosis area and cardiomyocyte apoptosis rate dose-dependently compared to MIRI controls. Reduced cleaved caspase 3 and Bax protein levels, and increased Bcl-2 protein levels compared to MIRI controls. Reduced myocardial ROS, serum MDA, and serum LPO levels, and increased serum SOD levels dose-dependently compared to MIRI controls. Reduced mitochondrial damage rate, improved mitochondrial structure, and reduced mitochondrial swelling and vacuolar degeneration dose-dependently compared to MIRI controls. Increased myocardial TGR5 and p-AMPK protein levels dose-dependently compared to MIRI controls. When combined with 100 mg/kg methyl rosmarinate, TGR5 overexpression further enhanced cardiac function, reduced myocardial injury markers, infarct size, pathological damage, oxidative stress, and mitochondrial damage, and further increased TGR5 and p-AMPK levels compared to methyl rosmarinate alone. TGR5 knockdown reversed the beneficial effects of methyl rosmarinate, reducing cardiac function, increasing injury markers, pathological damage, oxidative stress, and mitochondrial damage, and decreasing TGR5 and p-AMPK levels compared to methyl rosmarinate alone. |
|
| 性状 |
固体 |
| 颜色 |
White to light yellow |